Answers are grounded in this paper and cite their sources.
"Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group." Clinical Toxicology, 54(6), pp. 533–534
No takes yet. Share an insight, caveat, or question.
Rook et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: